• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Medicare proposes reimbursement cuts for Abiomed’s Impella

Medicare proposes reimbursement cuts for Abiomed’s Impella

April 17, 2017 By Brad Perriello

AbiomedThe Centers for Medicare & Medicaid Services is proposing to cut the reimbursement rate for treatment with the Impella heart pump made by Abiomed (NSDQ:ABMD) but is adding coverage for use of the pump in both chambers of the heart, the company said today in a regulatory filing.

The federal health insurer last week released draft hospital payment levels for fiscal year 2018 slated to begin in October. The proposal, for treatment using the Impella pump under various scenarios, would cut 3 of the 4 categories, 1 by nearly -34%.*

But CMS also proposed to cover biventricular implantation of the Impella device, CEO Michael Minogue told MassDevice.com today.

“If you blend it all in, [the biventricular implant coverage] is all new, so that is significantly higher than anything we had,” Minogue explained during a telephone interview. “The net effect is the overall coverage of Impella went up.”

The proposed rule is open for public comment until June 13 and is due to be released in August.

“Abiomed is reviewing the detailed data within the tables and will be discussing the appropriate [diagnostic related group] rates with CMS during the open comment period to confirm it accurately reflects the hospital resources required to treat these very ill patients,” the company said in the filing.

To us, Minogue stressed that the CMS proposal does not take into account any of Abiomed’s Impella data.

Here’s a look at the proposed changes for all hospitals in the Medicare & Medicaid systems:

Procedure Current rate
(all hospitals)
Proposed FY ’18 rate % change
Impella assistance in catheterization lab only $57,460 $57,622 0.4%
Impella implant with care after catheterization lab $95,971 $63,487 -33.9%
Biventricular implant $161,472 $152,464 -5.6%
ICU care and removal of Impella, after transfer from outlying hospital $37,564 $39,474 5.1%

Abiomed said its model for the effect of the proposed changes, based on 100 sites that use the Impella device, shows that the rate for Impella with after-care would be cut by -34.8%:

Procedure Current rate (100 Impella sites) Proposed FY ’18 rate % change
Impella assistance in catheterization lab only $70,299 $69,455 -1.2%
Impella implant with care after catheterization lab $117,413 $76,525 -34.8%
Biventricular implant $197,548 $183,776 -7.0%
ICU care and removal of Impella, after transfer from outlying hospital $45,957 $47,580 3.5%

Leerink Partners analyst Danielle Antalffy, writing in a note to investors today, said that the news is not as dire as it’s likely to be perceived on Wall Street.

“This rate cut may ultimately be less bad than feared, as it does not reflect any Impella claims, thus likely reflecting a lower cost run-rate than that post-October 2016,” Antalffy wrote. “To us, a proposed rate cut does not change the fundamental growth story for ABMD, which is a monopoly addressing a highly underpenetrated market opportunity with a critical unmet need.”

Antalffy also cited the biventricular pacing coverage as a positive for the company, adding that the proposal’s coverage of transfer from an outlying hospital valdiate’s Abiomed’s “hub-and-spoke” model, “better motivating hospitals to send critical patients to an Impella center.”

ABMD shares closed down -0.7% at $124.61 apiece April 14; the stock was trading at $119.82 per share in mid-morning activity today, down -3.8%.

* This article originally mis-calculated the percentage changes for the covered procedures. ↩

Filed Under: Structural Heart, Wall Street Beat Tagged With: Abiomed, Reimbursement

More recent news

  • FDA adds Gradient denervation tech to advisory program
  • Former Intuitive sales leader joins surgical robot maker Virtual Incision as CEO
  • Smith+Nephew to open first orthopedic ambulatory surgery center in the UK
  • Medtronic partners with IRCAD on Hugo, Affera surgical training
  • 23andMe co-founder wins bid to take back control of company

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy